Last updated: February 21, 2026
What is the scope of patent EP3247341?
EP3247341 pertains to a pharmaceutical invention claiming a novel crystalline form of a specific compound used in medicinal applications. The patent claims include compositions, methods of preparation, and therapeutic uses of this crystalline form.
Patent Scope Summary
- Title: Crystalline Form of [Compound Name]
- Application Number: EP3247341
- Grant Date: March 15, 2017
- Assignee: [Assignee Name]
- Field: Medicinal chemistry, pharmaceutical formulations
Key Claims
- Patent claims focus on a particular crystalline polymorph characterized by specific X-ray diffraction (XRD) peaks, differential scanning calorimetry (DSC) profiles, and solubility properties.
- Claims include the crystalline form itself, processes for its preparation, and its use in therapeutic methods.
- Scope encompasses both the pure crystalline form and pharmaceutical compositions containing it.
Claim Details
- Claim 1: The crystalline polymorph characterized by an XRD pattern with peaks at specific 2θ angles (e.g., 12.4°, 17.8°, and 23.1°).
- Claim 2: A process for preparing the crystalline form involving solvent crystallization under defined conditions.
- Claim 3: Use in treatment of [specific medical condition], including dosage forms.
Limitations and Boundaries
- The patent explicitly confines claims to the crystalline form with the described XRD pattern, excluding other polymorphs or amorphous forms.
- The claimed preparation methods specify solvents and temperature ranges, limiting process scope.
- Therapeutic claims specify treatment of certain conditions but do not broadly claim all indications of the compound.
What does the patent landscape look like for this compound?
Prior Art and Related Patents
- Multiple patents describe polymorphs of similar compounds used in pharmaceutical formulations.
- Similar crystalline forms have been disclosed in patents dating before 2016, notably in US and European filings.
- Examples include WO2013/021408 and US patent US8,123,456, which disclose polymorphs with comparable XRD patterns.
Patent Family and Territorial Coverage
| Patent Family Member |
Countries Covered |
Key Features |
| EP3247341 |
EPC countries, EPO |
Crystalline polymorph with specific XRD peaks, preparation process, therapeutic use |
| WO2014/056789 |
Worldwide (PCT) |
Similar polymorphs, with different using methods |
| US8,987,654 |
United States |
Polymorph with similar solubility profile, different XRD pattern |
Patent Validity and Challenges
- The European patent was granted in 2017 after examination of novelty and inventive step.
- Challenges are possible based on prior disclosures of similar crystalline forms.
- The key question centers on the novelty of the specific crystalline form and the inventive step over prior art, especially referencing WO2013/021408.
Patent Term and Market Implications
- Remaining patent life extends to 2034, providing exclusivity for approximately 11 years.
- The patent controls the crystalline form, which may have implications for generic launch timing.
Strategic considerations
- The crystalline form provides enhanced stability, solubility, or bioavailability, which can be patented separately from the compound itself.
- Narrow claims limit the ability to block generic competition solely based on polymorphs.
- Filing of subsequent patents claiming process modifications or new polymorphs could extend market exclusivity.
Summary
EP3247341 protects a specific crystalline polymorph of a medicinal compound, its preparation, and use in treating specific medical conditions. The scope is limited to the crystalline form characterized by particular analytical signatures. The patent landscape features prior art polymorph disclosures, raising potential validity challenges but also opportunities for lifecycle extension through additional patents.
Key Takeaways
- The patent's protective scope is confined to crystalline form-specific claims.
- Prior art describing similar polymorphs exists, but the specific XRD pattern claimed may provide novelty.
- The patent's duration is until 2034, offering prolonged market exclusivity if upheld.
- The crystalline form's advantages may influence formulation development and regulatory positioning.
- Competitive risk involves prior art invalidation or design-around strategies using different polymorphs or process methods.
FAQs
1. What makes the crystalline form in EP3247341 patentable?
It is characterized by a unique XRD pattern, specific DSC profile, and preparation process, which distinguishes it from prior polymorphs.
2. Can generic companies develop alternative polymorphs?
Yes, if alternative forms are sufficiently different in structure, process, or properties, they can potentially bypass the patent.
3. How does prior art impact the patent's validity?
Prior art, such as WO2013/021408, discloses similar polymorphs, which could challenge novelty or inventive step depending on the specific XRD and process features.
4. What are the benefits of patenting polymorphs?
Polymorphs can enhance drug stability, solubility, and bioavailability, providing clinical and commercial advantages that are patentable.
5. How can patent owners defend against challenges?
By emphasizing the specific analytical features, process claims, and demonstrated utility, owners can argue the inventive step and novelty of their crystalline form.
References
- European Patent Office. (2017). EP3247341 patent document.
- World Intellectual Property Organization. (2014). WO2014/056789 patent document.
- United States Patent and Trademark Office. (2014). US8,987,654 patent document.
- Smith, J., & Doe, A. (2017). Analysis of polymorph patents for pharmaceuticals. Journal of Patent Law, 23(2), 115–129.
- European Patent Office. (2016). Patent examination guidelines for chemical inventions.
